Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Grace Therapeutics, Inc GRCE

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.


NDAQ:GRCE - Post by User

Bullboard Posts
Post by Poppson Dec 17, 2012 9:38pm
221 Views
Post# 20743052

BUY BACK YOUR STOCK ! ! !

BUY BACK YOUR STOCK ! ! !

Good APO news today that we've been waiting for............then some frigging squirrel shorts Neptune and  writes an article highlighting all the worst possible interpretations of recent events THAT  WE  ALREADY  KNOW  ABOUT.  I saw the article when it first came out, saw he was short, and cussed him appropriately.  Later, I couldn't believe the market reaction..... this is no reason to bail from Neptune.   TO  BAIL  FROM  ACASTI  IS  EVEN  A  WORSE  DECISION.   How is the approval progress of the drug(s) in the pipeline related to this guy's diatribe??  It is not.  I bought a chunk today, but I don't really want to profit  by  taking advantage retail investors (like you & I), but rather from the sure-thing we have in front of us.  I have a buy order in for more shares at $0.02 lower than I bought today in case folks keep bailin'.   IT'S  ON  SALE  NOW,  BUY  IT  BACK  ! !

Popps

Bullboard Posts